open access
Cost-effectiveness analysis of adjunctive hyperbaric oxygenations in diabetic feet ulcer: a systematic review
, 1, 3, 1
Affiliations- Gadjah Mada University, Bulaksumur, Caturtunggal, Kec. Depok, Kabupaten Sleman, Daerah Istimewa Yogyakarta, Sleman, Indonesia
- Pharmacy Department, Hang Tuah University, Arif Rahman Hakim, Surabaya, Indonesia
- Department of Internal Medicine, Dr. Ramelan Navy Hospital, Surabaya, Indonesia
open access
Abstract
Background: Hyperbaric oxygen therapy (HBOT) has been reported to be beneficial in enhancing wound
healing and preventing amputations in diabetic foot ulcers (DFU), though not many studies are available
to demonstrate how cost-effective this treatment is. A comprehensive assessment of cost-effectiveness
evaluations about hyperbaric oxygen therapy (HBOT) considering financial viability into account is critical
and essential.
Objective: To assess the cost-effectiveness of HBOT in DFU patients.
Materials and methods: A systematic search (October 2023) was performed in 3 databases: PUBMED,
EMBASE, and Cochrane CENTRAL. The study was guided by the PICO research question as detailed (Population:
DFU patients; Intervention: HBOT; Comparison: standard care; Outcome: ICER). Cost-effectiveness
analyses (CEAs) involving interventions in DFU patients with Wagner III and above were included. The main
outcomes of this review were costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness
ratio (ICER). The CHEERS checklist was used to assess the quality of CEAs.
Results: Two studies revealed the cost-effectiveness of standard wound care (SWC) plus HBOT, whereas
one study showed that HBOT was not cost-effective as adjunctive treatment for DFU. The ICER of HBOT
in 12 years were $2,255/QALY and US$2621/QALY.
Conclusion: The evidence to support the cost-effectiveness of HBOT is insufficient. However, the majority
of HBOT studies have reported this therapy was cost-effective. Instead of model-based evaluations,
further studies should combine clinical application of interventions with concomitant economic assessment.
Abstract
Background: Hyperbaric oxygen therapy (HBOT) has been reported to be beneficial in enhancing wound
healing and preventing amputations in diabetic foot ulcers (DFU), though not many studies are available
to demonstrate how cost-effective this treatment is. A comprehensive assessment of cost-effectiveness
evaluations about hyperbaric oxygen therapy (HBOT) considering financial viability into account is critical
and essential.
Objective: To assess the cost-effectiveness of HBOT in DFU patients.
Materials and methods: A systematic search (October 2023) was performed in 3 databases: PUBMED,
EMBASE, and Cochrane CENTRAL. The study was guided by the PICO research question as detailed (Population:
DFU patients; Intervention: HBOT; Comparison: standard care; Outcome: ICER). Cost-effectiveness
analyses (CEAs) involving interventions in DFU patients with Wagner III and above were included. The main
outcomes of this review were costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness
ratio (ICER). The CHEERS checklist was used to assess the quality of CEAs.
Results: Two studies revealed the cost-effectiveness of standard wound care (SWC) plus HBOT, whereas
one study showed that HBOT was not cost-effective as adjunctive treatment for DFU. The ICER of HBOT
in 12 years were $2,255/QALY and US$2621/QALY.
Conclusion: The evidence to support the cost-effectiveness of HBOT is insufficient. However, the majority
of HBOT studies have reported this therapy was cost-effective. Instead of model-based evaluations,
further studies should combine clinical application of interventions with concomitant economic assessment.
Keywords
HBOT; cost-effectiveness; DFU; diabetic wound; cost
About this articleTitle
Cost-effectiveness analysis of adjunctive hyperbaric oxygenations in diabetic feet ulcer: a systematic review
Journal
Issue
Article type
Review article
Pages
35-42
Published online
2024-03-29
Page views
59
Article views/downloads
30
DOI
10.5603/imh.98770
Bibliographic record
IMH 2024;75(1):35-42.
Keywords
HBOT
cost-effectiveness
DFU
diabetic wound
cost
Authors
Ana Khusnul Faizah
Tri Murti Andayani
Libriansyah
Dwi Endarti
References (35)- IDF Diabetes Atlas. https://diabetesatlas.org/atlas/ninth-edition/ (02.12.2023).
- IDF DIABETES ATLAS, 10th edition. https://www.ncbi.nlm.nih.gov/books/NBK581934/ (02.12.2023).
- DiPiro JT, Yee GC, Posey M. Pharmacotherapy: A Pathophysiologic Approach. 2020.
- Shaheen MMA, Al Dahab S, Abu Fada M, et al. Isolation and characterization of bacteria from diabetic foot ulcer: amputation, antibiotic resistance and mortality rate. Int J Diabetes Dev Ctries. 2022; 42(3): 529–537.
- Kruse I, Edelman S. Evaluation and treatment of diabetic foot ulcers. Clinical Diabetes. 2006; 24(2): 91–93.
- Raghav A, Khan ZA, Labala RK, et al. Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always. Ther Adv Endocrinol Metab. 2018; 9(1): 29–31.
- Butt MD, Ong SC, Wahab MU, et al. Cost of illness analysis of type 2 diabetes mellitus: the findings from a lower-middle income country. Int J Environ Res Public Health. 2022; 19(19).
- Jodheea-Jutton A, Hindocha S, Bhaw-Luximon A. Health economics of diabetic foot ulcer and recent trends to accelerate treatment. Foot (Edinb). 2022; 52: 101909.
- Armstrong DG, Swerdlow MA, Armstrong AA, et al. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020; 13(1): 16.
- IWGDF Guideline on interventions to enhance healing of foot ulcers in persons with diabetes. www.iwgdfguidelines.org (02.12.2023).
- Capó X, Monserrat-Mesquida M, Quetglas-Llabrés M, et al. Hyperbaric oxygen therapy reduces oxidative stress and inflammation, and increases growth factors favouring the healing process of diabetic wounds. Int J Mol Sci. 2023; 24(8).
- Memar MY, Ghotaslou R, Samiei M, et al. Antimicrobial use of reactive oxygen therapy: current insights. Infect Drug Resist. 2018; 11: 567–576.
- Yıldırım AO, Eryılmaz M, Kaldırım U, et al. Effectiveness of hyperbaric oxygen and ozone applications in tissue healing in generated soft tissue trauma model in rats: an experimental study. Ulus Travma Acil Cerrahi Derg. 2014; 20(3): 167–175.
- Sunkari VG, Lind F, Botusan IR, et al. Hyperbaric oxygen therapy activates hypoxia-inducible factor 1 (HIF-1), which contributes to improved wound healing in diabetic mice. Wound Repair Regen. 2015; 23(1): 98–103.
- Hisamuddin N, Zahiruddin WN, Yazid BM, et al. Use of hyperbaric oxygen therapy (HBOT) in chronic diabetic wound — a randomised trial. Med J Malaysia. 2019; 74(5): 418–424.
- Oley MH, Oley MC, Islam AA, et al. Hyperbaric oxygen therapy in managing systemic inflammatory response syndrome caused by ischemia-reperfusion injury following hand replantation and long-term outcomes: A report of two cases. Ann Med Surg (Lond). 2020; 60: 155–161.
- Sharma R, Sharma SK, Mudgal SK, et al. Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials. Sci Rep. 2021; 11(1): 2189.
- Moreira DA Cruz DL, Oliveira-Pinto J, Mansilha A. The role of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers: a systematic review with meta-analysis of randomized controlled trials on limb amputation and ulcer healing. Int Angiol. 2022; 41(1): 63–73.
- “PRISMA”. http://www.prisma-statement.org/PRISMAStatement/ (02.12.2023).
- Aslam S, Emmanuel P. Formulating a researchable question: a critical step for facilitating good clinical research. Indian J Sex Transm Dis AIDS. 2010; 31(1): 47–50.
- Husereau D, Drummond M, Augustovski F, et al. CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022; 20(1): 23.
- Hope SF, Webster J, Trieu K, et al. A systematic review of economic evaluations of population-based sodium reduction interventions. PLoS One. 2017; 12(3): e0173600.
- Langer A. A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments. BMC Health Serv Res. 2012; 12: 253.
- Guo S, Counte MA, Gillespie KN, et al. Cost-effectiveness of adjunctive hyperbaric oxygen in the treatment of diabetic ulcers. Int J Technol Assess Health Care. 2003; 19(4): 731–737.
- Thiruvoth FM, Rajasulochana S, S M, et al. Hyperbaric oxygen therapy as an adjunct to the standard wound care for the treatment of diabetic foot ulcers in Indian patients: a cost utility analysis. xpert Rev Pharmacoecon Outcomes Res. 2022; 22(7): 1087–1094.
- Chuck AW, Hailey D, Jacobs P, et al. Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. Int J Technol Assess Health Care. 2008; 24(2): 178–183.
- Vas P, Rayman G, Dhatariya K, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2020; 36 Suppl 1: e3284.
- Chen L, Zhang S, Da J, et al. A systematic review and meta-analysis of efficacy and safety of negative pressure wound therapy in the treatment of diabetic foot ulcer. Ann Palliat Med. 2021; 10(10): 10830–10839.
- Lim JZ, Ng NS, Thomas C. Prevention and treatment of diabetic foot ulcers. J R Soc Med. 2017; 110(3): 104–109.
- Everett E, Mathioudakis N. Update on management of diabetic foot ulcers. Ann N Y Acad Sci. 2018; 1411(1): 153–165.
- Core MD, Ahn J, Lewis R, et al. The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot Ankle Orthop. 2018; 3(3): 247301141878886.
- Elraiyah T, Tsapas A, Prutsky G, et al. A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers. J Vasc Surg. 2016; 63(2 Suppl): 46S–58S.e1.
- Tuglo LS, Nyande FK, Agordoh PD, et al. Knowledge and practice of diabetic foot care and the prevalence of diabetic foot ulcers among diabetic patients of selected hospitals in the Volta Region, Ghana. Int Wound J. 2022; 19(3): 601–614.
- Home — TreeAge Software. https://www.treeage.com/ (02.12.2023).
- Woods TJ, Tesfay F, Speck P, et al. Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: a systematic review. PLoS One. 2020; 15(4): e0232395.
